about
CD133 antigen expression in ovarian cancerPost-translational regulation of CD133 by ATase1/ATase2-mediated lysine acetylationNon-invasive in vivo imaging of tumor-associated CD133/promininCD133, Selectively Targeting the Root of CancerAberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinomaGenome and transcriptome profiles of CD133-positive colorectal cancer cells.Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line.The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cellsThe endoplasmic reticulum-based acetyltransferases, ATase1 and ATase2, associate with the oligosaccharyltransferase to acetylate correctly folded polypeptidesCD117⁺ cells in the circulation are predictive of advanced prostate cancerOvarian cancer stem cell markers: prognostic and therapeutic implications.Aberrant Expression of Cancer Stem Cells Marker Prominin-1 in Low-Grade Tubulolobular Breast Carcinoma: A Correlative Study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis [corrected].Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.Induction of cancerous stem cells during embryonic stem cell differentiation.Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties.Symptomatic cardiac metastases of breast cancer 27 years after mastectomy: a case report with literature review--pathophysiology of molecular mechanisms and metastatic pathways, clinical aspects, diagnostic procedures and treatment modalities.In vitro expansion of human glioblastoma cells at non-physiological oxygen tension irreversibly alters subsequent in vivo aggressiveness and AC133 expression.Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiationHuman osteosarcoma CD49f(-)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity.Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer.CD133-targeted niche-dependent therapy in cancer: a multipronged approach.The challenges of integrating molecular imaging into the optimization of cancer therapy.CD133+ cells as a therapeutic target for kidney diseases.CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges.Stem cells and cancer stem-like cells in endocrine tissues.Cancer stem cell markers: what is their diagnostic value?A bispecific EpCAM/CD133-targeted toxin is effective against carcinomaEnhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions.CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope.Growth kinetics of CD133-positive prostate cancer cells.Trending Speculations of Tumor-Initiating Cells in Squamous Cell Cancers of Head and NeckRalA is overactivated in medulloblastoma.Cytoprotective effect of neuropeptides on cancer stem cells: vasoactive intestinal peptide-induced antiapoptotic signaling.Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker.The clinicopathological parameters significance of CD133 and Nestin in epithelial ovarian cancer: a meta-analysis.CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial.
P2860
Q21093306-1B46C5A4-F57F-47B3-922B-4BD39F17FA3BQ24337923-576AE2A0-C009-41BA-895C-3A3E25DF917AQ27438105-1B24A1FA-FB5E-4B1D-8FD0-EB2ABC1893CBQ28066353-21B95B96-1B4D-40FA-9E21-B2F49EF2B027Q33582684-21D64DF9-8953-4CC8-9A94-627ADF8D22D8Q33855041-531E7810-4F3E-4997-97A5-76113E624499Q33955042-D0A36B56-C6C6-4E33-B972-810044E45225Q34038381-2CDDB450-AB34-4307-9487-ED605B8A230CQ34509754-7B92C8EC-19CE-4B32-9746-FB106198EE92Q35176469-D7E2A247-8D1F-41D1-8922-0BFA6FE4D1ABQ35606242-874F7CCE-9EF7-4916-872D-02FF699047F7Q35866920-AF993926-C967-4200-AE72-47865BF4F1ACQ35888438-B21FD234-BC70-4656-8FE8-BA31E7677344Q36347664-1D628D94-6B31-48C3-83A8-B01686670EFBQ36545955-FAF78A83-0E1A-4D5D-BECA-1DFF77334584Q36581353-23CC7457-6475-4201-A632-A64B17BC7DF9Q36645642-AAE481CD-6ED8-431B-BA0E-06A71F0CEAFBQ36664232-C6BC7975-BFD4-4976-8790-8EDD321067F2Q37626756-2587F31F-C486-406C-900E-E13FAA8489B2Q37702117-9C7A93B3-A565-4709-801A-BA920B9903E8Q37734881-9AD371D3-7BDC-408A-B0DA-55A89652665FQ37871875-B0CC5FB3-6FEA-47D2-9C3B-A790C3D9B868Q37983119-1F4E155B-FD4C-40ED-B181-D87FEE85EE84Q38035206-BF93EC04-CED0-4411-9250-CBE63E564887Q38084129-B9DAA165-2DF8-4410-9BC0-F401541792FEQ38089898-FDA6A122-4CA4-45BA-A34F-6BB25ED4BB42Q38867217-8AA9AEB7-792E-4E31-9C45-62F692F3D270Q39129183-02173760-552B-499C-AFD1-377AC7EDD5ACQ39243687-EFA3BD43-F084-4799-9247-E685A039EA56Q39247506-522C8966-809B-4405-AB32-AAED8073C6DFQ39264794-5CC5A8E6-E53E-4A80-8E67-FD68A5E281E9Q39449209-E305C7A8-28AF-4E29-BC36-60FBAA71F3C5Q41083994-4BA814B9-E277-41EA-B42D-ED4D18D6F384Q41573313-3A218B8A-18B2-4700-A423-09339A1D8852Q42221543-5EDD063E-1FFD-451A-9DA7-35454F0D3117Q47821773-C75003FE-6AF9-448D-BA2A-1BE47B483817Q55477963-66844F69-A2B7-47CE-B869-0D4B45372D70
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting CD133 antigen in cancer.
@en
Targeting CD133 antigen in cancer.
@nl
type
label
Targeting CD133 antigen in cancer.
@en
Targeting CD133 antigen in cancer.
@nl
prefLabel
Targeting CD133 antigen in cancer.
@en
Targeting CD133 antigen in cancer.
@nl
P2093
P2860
P1476
Targeting CD133 antigen in cancer.
@en
P2093
Gabriella Ferrandina
Giovanni Scambia
Giuseppina Bonanno
Marco Petrillo
P2860
P304
P356
10.1517/14728220903005616
P407
P577
2009-07-01T00:00:00Z